CC-31244

N/A

Report date: 2024/06/11 20:00:08
NME

Base Information

Drug NameCC-31244
Drug Alias NameCDI-31244NS5B NNICC-31244
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesHong Kong
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCocrystal Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCocrystal Pharma IncHumanity & Health Medical Group Ltd
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A